Navigation Links
'MicroRNA' could be key target for bowel cancer treatment
Date:4/14/2014

Scientists found that the molecule, called microRNA 135b, is a vital 'worker' employed by several important cancer genes to drive the growth of bowel cancers.

Drugs targeted at the microRNA could knock out the effects of multiple cancer-causing mutations at once, while tests for it could identify patients with the most aggressive disease, the researchers believe.

The research was carried out by an international team including scientists based at The Institute of Cancer Research, London, the University of Glasgow and Ohio State University in the US.

Scientists tested for microRNA 135b in 485 patients with bowel cancer and found that levels were at least four times as high in tumours as in healthy tissue, and that patients with the highest levels survived the least long.

They showed that blocking the microRNA stopped tumour growth in bowel cancer mouse models, and in half of them tumours regressed so dramatically they could no longer be seen by imaging. Mice didn't show any side-effects as a result of treatment.

The study is published today (Monday) in the prestigious journal Cancer Cell, with funding for the UK research team coming from the Kimmel Cancer Foundation, Cancer Research UK, The Marie Curie Actions Programme and a Scottish Senior Clinical Research Fellowship.

MicroRNAs are small strands of genetic material that regulate gene activity and are involved many cellular processes.

The study showed that a number of known cancer gene mutations, such as APC, PI3KCA, SRC and p53, exercise their effects through microRNA 135b.

Although treatments targeting bowel cancer mutations have been developed, patients often develop resistance. Inhibiting microRNA 135b could be an exciting way to attack cancers without resistance occurring by blocking the effects of multiple cancer-causing mutations simultaneously.

The findings also suggest that testing levels of microRNA 135b could help identify patients likely to develop aggressive bowel cancer, and who might need the most intensive treatment.

Lead author Dr Nicola Valeri, Leader of the Gastrointestinal Cancer Biology and Genomics Team at The Institute of Cancer Research, London, said:

"We have shown that a specific microRNA can drive the development of bowel cancers and is a key 'worker' responsible for putting into action the instructions from many cancer-causing mutations. Patients with the highest levels of this molecule have the most difficult-to-treat cancers, and inhibiting the molecule in mice prevents tumours from growing. Although the research is at an early stage, our findings may have an important impact in the way we treat patients with bowel cancer in the future."

Professor Paul Workman, Deputy Chief Executive of The Institute of Cancer Research, London, said: "This work sheds light on the important role of microRNAs in bowel cancer and opens up a potentially exciting new avenue for cancer treatment. It also gives us a marker of disease that might prove valuable in the clinic to predict which patients have a more aggressive cancer.

"MicroRNAs play a vital role in the cells in our body, both in normal functions and in disease. We have known for a while that microRNAs are important in cancer, but their diversity of roles has meant it's been difficult to target them with drugs without causing toxic side-effects. This particular RNA has a huge advantage that might allow us to avoid this toxicity, because it is found in very low levels in normal tissue and in high levels in cancer."

Professor Owen Sansom, Deputy Director of The Cancer Research UK Beatson Institute at Glasgow University, said: "This exciting work shows a single microRNA can control multiple pathways that go wrong in colon cancer and offers the hope that in the future this could be targeted in patients that have colon cancer."


'/>"/>

Contact: Graham Shaw
graham.shaw@icr.ac.uk
44-207-153-5380
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. A microRNA prognostic marker identified in acute leukemia
2. Pint-size microRNAs show promise against weighty problem, researchers say
3. MicroRNAs can convert normal cells into cancer promoters
4. Hepatitis B virus promotes oncogenesis through microRNA modulation
5. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
6. Atherosclerosis: Specific microRNAs promote inflammation
7. Moffitt Cancer Center researchers say 1 specific microrna promotes tumor growth and cancer spread
8. New papers identify a microRNA that drives both cancer onset and metastasis
9. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
10. Versatile microRNAs choke off cancer blood supply, suppress metastasis
11. MicroRNA-31 might predict lung-cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American ... function testing company, is now able to perform sophisticated lung assessments ... ndd Medical Technologies , Inc. Patients are no ...  Thanks to ndd,s EasyOne PRO ® , ARL patients like Jeanne ... needed testing done in the comfort of her own home. ...
Breaking Medicine Technology: